9.50
0.22 (2.37%)
| Penutupan Terdahulu | 9.28 |
| Buka | 9.60 |
| Jumlah Dagangan | 59,889 |
| Purata Dagangan (3B) | 22,882 |
| Modal Pasaran | 47,734,176 |
| Harga / Buku (P/B) | 0.430 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Mar 2025 - 17 Mar 2025 |
| EPS Cair (TTM) | -11.73 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.48% |
| Nisbah Semasa (MRQ) | 22.63 |
| Aliran Tunai Operasi (OCF TTM) | -67.70 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.10 M |
| Pulangan Atas Aset (ROA TTM) | -22.33% |
| Pulangan Atas Ekuiti (ROE TTM) | -45.37% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | AlloVir, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.0 |
| Purata | -0.67 |
|
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 34.46% |
| % Dimiliki oleh Institusi | 50.64% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |